In 2006 the New England Journal of Medicine published results from 36,282 postmenopausal women who had been randomly assigned, for an average of seven years, to either calcium plus vitamin D or a placebo. The supplements produced a small gain in hip bone density. They did not significantly reduce hip fractures. And they raised the risk of kidney stones, with a hazard ratio of 1.17.
That trial is the Women’s Health Initiative calcium and vitamin D study, and it is the single most informative thing anyone has run on this question. Twenty years later, the federal fact sheet that reports its kidney stone finding describes the underlying evidence as observational.
Calcium is the nutrient where supplementing has the best-documented case for a real downside, and the field has not settled it. What follows: the published figures, the trials on both sides, and the places where authoritative sources read the same evidence differently. These are reports of what agencies and journals say. Nothing below is advice: this page does not tell anyone to start a supplement, stop one, or change a dose.
The published figures, and the split at 51
The Food and Nutrition Board of the National Academies sets the US figures, and the NIH Office of Dietary Supplements publishes them. Article 322 covers the Dietary Reference Intake framework and article 323 covers upper limits as a concept.
| Group | RDA, mg/day | Upper limit, mg/day |
|---|---|---|
| Men and women 19-50 | 1,000 | 2,500 |
| Pregnancy and lactation 19-50 | 1,000 | 2,500 |
| Men 51-70 | 1,000 | 2,000 |
| Women 51-70 | 1,200 | 2,000 |
| Men and women 71+ | 1,200 | 2,000 |
The detail most often got wrong is that men and women part company at 51. A woman’s RDA rises to 1,200 mg then; a man’s stays at 1,000 until 71. Note also that the upper limit drops at 51 while the recommended intake rises, so the gap between the two narrows with age.
Scope matters for any upper limit, meaning what the number is counting. The ODS calcium fact sheet does not say. The National Academies’ default on the DRI tables is total intake from food, water and supplements, and the clearest attributable statement comes from a professional-body guideline: the 2016 joint clinical guideline from the National Osteoporosis Foundation and the American Society for Preventive Cardiology describes the National Academy of Medicine’s upper level as 2,000 to 2,500 mg a day for calcium from food and supplements combined.
A kidney stone finding, and a dispute about what kind of study it came from
ODS reports that the Food and Nutrition Board’s upper limits rest on observational evidence from the Women’s Health Initiative linking higher supplemental calcium intake, at 1,000 mg a day for seven years, to greater kidney stone risk.
The study producing that result was not observational. Rebecca Jackson and colleagues reported the WHI calcium and vitamin D trial in 2006: 36,282 postmenopausal women aged 50 to 79, randomly assigned to 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 daily, or placebo, followed an average of 7.0 years. Renal calculi increased in the supplement group, hazard ratio 1.17, with a 95 percent confidence interval of 1.02 to 1.34. Hip bone density was about 1 percent higher. Hip fracture showed a hazard ratio of 0.88, confidence interval 0.72 to 1.08, which does not exclude no effect. Total fractures came in at 0.96.
Two authoritative renderings of one body of evidence therefore disagree about its study design, and the difference is not cosmetic. A randomized trial assigns people to treatment by chance, which is what lets researchers attribute a difference in outcomes to the treatment itself. An observational association can always be explained by something that differed between the groups to begin with. Which rendering you accept therefore changes how much weight the kidney stone finding carries. This site reports both and resolves neither.
The same trial also shows how much one analytic choice can move a result. When the researchers censored data from women once they stopped taking the study pills, the hazard ratio for hip fracture dropped from 0.88 to 0.71, confidence interval 0.52 to 0.97. On the intention-to-treat analysis the supplements did not significantly prevent hip fracture; among the women who kept taking them, they appear to have done so. Both numbers come from the same paper, and which one gets quoted changes the story.
ODS also carries the counter-evidence, and it is real. It describes two later systematic reviews that found no such association: one covering 10 studies in more than 8,000 adults with osteoporosis taking 120 to 1,500 mg of supplemental calcium daily, and one covering 11 randomized trials in 51,419 adults aged 50 and older taking 1,000 to 1,600 mg, with or without vitamin D, for two to seven years.
The cardiovascular argument that never resolved
This is the part of the subject where the disagreement is loudest, and it has been running since 2010.
Why a pill might differ from a glass of milk
The proposed mechanism is worth understanding, because it explains why anyone thought to look. Ian Reid and colleagues set it out in a 2017 review: circulating calcium is itself a risk factor for vascular disease, a conclusion drawn from prospective studies covering hundreds of thousands of people over periods of up to 30 years. Some of that association runs through other risk factors such as blood lipids, blood pressure and body mass index, but a residual independent effect of serum calcium appears to remain. They add that genetic variants in the calcium-sensing receptor linked to small elevations in serum calcium are also linked to cardiovascular disease, which points toward calcium playing a causal part rather than merely tracking something else.
A supplement delivers a large load at once; a meal delivers calcium slowly, alongside protein, fat and other minerals. That is the hypothesis. It is a hypothesis rather than a demonstrated mechanism, and the trials below were not designed to test it.
The case that supplements raise risk
In 2010 Mark Bolland and colleagues published a meta-analysis in the BMJ covering 15 placebo-controlled trials of calcium supplements. Across the five trials supplying individual patient data, 8,151 participants followed a median of 3.6 years, 143 people on calcium had a heart attack against 111 on placebo, a hazard ratio of 1.31 with a confidence interval of 1.02 to 1.67. The trial-level analysis, covering 11 trials and 11,921 participants, gave a pooled relative risk of 1.27 for heart attack. Stroke rose too, to a relative risk of 1.20, but its confidence interval of 0.96 to 1.50 does not exclude no effect, and the same was true for death. Their conclusion was blunt: “Calcium supplements (without coadministered vitamin D) are associated with an increased risk of myocardial infarction.”
A 2011 follow-up in the same journal took on the obvious objection, which is that the WHI trial had found nothing of the kind. Bolland’s group reanalyzed the WHI dataset and reported an interaction nobody had accounted for. At randomization, 46 percent of participants, 16,718 women, were not already taking calcium supplements of their own. In that group, hazard ratios for cardiovascular events ran from 1.13 to 1.22. Among women already taking calcium, allocation to more calcium changed nothing, which is roughly what you would expect if the risk attaches to starting supplements rather than to the dose. Pooling eight calcium-supplement trials with the WHI women who had not been taking their own supplements, 28,072 participants in all, gave a relative risk of 1.24 for heart attack.
ODS carries related figures from other work: a meta-analysis of 14 randomized trials in 28,935 healthy postmenopausal women, in which supplements of 500 to 2,000 mg a day for one to seven years raised cardiovascular disease risk by 15 percent; a large observational cohort in which cardiovascular mortality ran 22 percent higher among men taking 1,000 mg a day or more of supplemental calcium, while running 16 percent lower among women at the same intake; and the WHI long-term follow-up, median 22.3 years, in which women given calcium and vitamin D had a 6 percent higher risk of cardiovascular death.
The case that there is no relationship
In 2016 an expert panel convened by the National Osteoporosis Foundation and the American Society for Preventive Cardiology published a clinical guideline in Annals of Internal Medicine reaching the opposite conclusion. Their position was that “there is moderate-quality evidence (B level) that calcium with or without vitamin D intake from food or supplements has no relationship (beneficial or harmful)” to cardiovascular and cerebrovascular disease, mortality or all-cause mortality in generally healthy adults. They added that intake within the 2,000 to 2,500 mg upper level should be considered safe from a cardiovascular standpoint.
Then the detail that explains why this never resolved. The panel built its conclusion on an updated systematic review by a Tufts team and a 2009 federal evidence report. Its reference list runs to six items. Bolland is not among them. A guideline from two professional societies concluded that no relationship exists without engaging the meta-analyses that argued one does.
ODS reports supporting evidence for this side as well, including the Nurses’ Health Study, in which 74,245 women followed for 24 years showed no higher cardiovascular risk with supplemental calcium, and a 27-study systematic review that found no consistent dose-response relationship.
A third US body declined to take a side at all. In June 2022 the US Preventive Services Task Force issued an I statement for single or paired nutrient supplements other than beta-carotene and vitamin E, in community-dwelling nonpregnant adults, meaning the evidence was insufficient to weigh benefits against harms for preventing cardiovascular disease or cancer. Insufficient evidence is not evidence of no effect, and it is not evidence of harm. It is a formal statement that the question remains open.
Two bodies of evidence, three professional readings, no reconciliation. For the general problem of what a large trial can settle, see article 326.
Food calcium and supplement calcium are not the same question
The sensible question is whether a supplement does what the food does, and the evidence treats the two differently.
Reid, Sarah Birstow and Mark Bolland reported in 2017 that observational studies of dietary calcium do not show a consistent adverse cardiovascular effect, though very high or very low intakes may be harmful, and that obtaining calcium from diet rather than supplements is to be encouraged. That is one of the authors of the meta-analyses saying the problem looks specific to supplements. The NOF and ASPC guideline, by contrast, treats food and supplements as equivalent, covering both in the same sentence.
Kidney disease is where that review finds its clearest signal. Reid’s group reports that trials of calcium supplements in people on dialysis, and in people with less severe kidney failure, show increased mortality, accelerated vascular disease, or both. That is a different population from the postmenopausal women in the WHI, and a reason why anyone with reduced kidney function has a genuinely different calculation to make, with a nephrologist rather than from a label.
Absorption differs too, and the numbers are concrete. ODS reports that the body absorbs about 45 percent of calcium at an intake of 200 mg a day but only about 15 percent above 2,000 mg, and that absorption from supplements is highest at single doses of 500 mg or less, running about 36 percent from a 300 mg dose and 28 percent from a 1,000 mg dose. Calcium carbonate is about 40 percent elemental calcium by weight and calcium citrate about 21 percent, so the pill sizes differ for the same delivered amount. Carbonate dissolves poorly when stomach acid is low and ODS says it causes more gastrointestinal side effects than citrate.
One finding runs the other way. On prostate cancer, ODS reports that only calcium from dairy foods was significantly associated with risk, while nondairy and supplemental calcium were not.
What shortfall does, and who is short
Calcium builds and maintains the skeleton, and it also runs muscle contraction, nerve signaling and blood clotting. The body holds blood calcium in a narrow range by pulling from bone when intake falls, which is why a blood test is a poor measure of dietary adequacy.
Long-term shortfall contributes to osteoporosis, meaning weak and fragile bones with higher fracture risk. ODS also names rickets in children and osteomalacia, poorly mineralized bone, in children and adults, while noting those are more commonly caused by vitamin D deficiency; article 327 owns vitamin D as a nutrient. Low blood calcium itself, hypocalcemia, usually traces to vitamin D or magnesium deficiency, parathyroid problems, certain medications or critical illness rather than to diet, and is often symptomless when mild.
Intakes fall short for a lot of people. ODS reports that in NHANES 2007 to 2010, 39 percent of Americans aged 4 and older, and 49 percent of children aged 4 to 18, consumed less than the Estimated Average Requirement from foods and supplements combined. The Estimated Average Requirement is the figure built for judging groups, which is exactly what those percentages are doing, and it sits below the RDA by design.
The groups ODS names as more likely to fall short are postmenopausal women, whose bone loss accelerates after estrogen declines, and people who avoid dairy because of lactose intolerance, milk allergy or a vegan diet. The page’s own figures also show lower adequacy among non-Hispanic Black and non-Hispanic Asian people and among people living in poverty. Article 335 covers intake across life stages.
What excess does
The upper limit exists because of documented harm above it. Excess calcium produces hypercalcemia, meaning too much calcium in the blood, with constipation, nausea, excessive thirst and frequent urination, and in severe cases confusion, kidney problems and heart rhythm disturbance. Kidney stones are the harm the WHI trial measured directly, and the harm the upper limit was built around.
The absorption ceiling matters here too. Because the body takes up a smaller share of each dose as the dose rises, a large single amount leaves more calcium unabsorbed in the gut, which is where the constipation comes from.
Calcium also interferes with several medications by binding them in the gut. ODS names four: dolutegravir, an HIV medication whose blood levels calcium can substantially reduce; levothyroxine, where the FDA-approved label advises against taking it within four hours of a calcium carbonate supplement; quinolone antibiotics such as ciprofloxacin, where taking the antibiotic two hours before or after prevents the effect; and lithium, where ODS says long-term use can lead to high blood calcium and adding calcium supplements could increase that risk. Article 677 covers interactions in full, and the timing rules there matter more than most people realize.
Two situations here are not label-reading problems at all. A history of calcium kidney stones changes the calculation entirely, because the trial evidence of harm is specifically about stone formation. And anyone taking levothyroxine, a quinolone or dolutegravir has a timing problem to work out with a pharmacist, since the interaction is about when the two are taken, not whether.
Questions this evidence can and cannot answer
Three questions of our own, drawn from where the sources above diverge.
Is the claim about food or about supplements? Reid and colleagues separate them; the NOF and ASPC guideline does not. Any summary that blurs the two is reporting something neither source said.
Is the figure a total or a supplement dose? The RDA and the upper limit both count food. A 1,000 mg supplement on top of a dairy-rich diet is not 1,000 mg of intake.
Does the source engage the other side? The strongest signal in this literature is that a 2016 professional guideline concluded no relationship exists, from a reference list of six that omits the papers arguing otherwise. When a summary of a contested field cites only one side, the citation list tells you more than the conclusion does.
What to take from this
The honest summary is that the field disagrees, and the disagreement is not between serious researchers and cranks. It is between a pair of BMJ meta-analyses and a joint guideline in Annals of Internal Medicine, none of them withdrawn, none of them answering each other.
What is not in dispute: the WHI trial found more kidney stones, with a hazard ratio of 1.17 and a confidence interval that excludes no effect. Dietary calcium has not produced a comparable cardiovascular signal in observational studies, though Reid’s group adds that very high or very low intakes may be harmful. And the upper limits, 2,500 mg a day to age 50 and 2,000 mg after, count what you eat as well as what you swallow from a bottle.
That last point is the one worth carrying. Anyone adding up their calcium starts with the yogurt, the cheese and the fortified cereal, because the published limits already count all of it, and a supplement is the last term in that sum rather than the first. A clinician or pharmacist who can see the whole total, and who knows whether you have ever passed a stone or had a kidney function test come back abnormal, is the person to do the arithmetic with.
Sources
- NIH Office of Dietary Supplements. “Calcium – Health Professional Fact Sheet.” ods.od.nih.gov
- National Academies of Sciences, Engineering, and Medicine, Food and Nutrition Board. “Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels, Vitamins and Elements (table footnotes).” nationalacademies.org
- US Preventive Services Task Force. “Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: Preventive Medication (final recommendation, June 21, 2022).” uspreventiveservicestaskforce.org
- Bone Health and Osteoporosis Foundation (formerly National Osteoporosis Foundation) and American Society for Preventive Cardiology. “Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults (joint clinical guideline, 2016).” bonehealthandosteoporosis.org
- Annals of Internal Medicine (National Osteoporosis Foundation and American Society for Preventive Cardiology clinical guideline), via PubMed. “Kopecky SL et al. "Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology." Ann Intern Med, 2016. DOI: 10.7326/M16-1743.” doi.org
- New England Journal of Medicine, via PubMed. “Jackson RD et al. "Calcium plus vitamin D supplementation and the risk of fractures." N Engl J Med, 2006. DOI: 10.1056/NEJMoa055218.” doi.org
- BMJ, via PubMed. “Bolland MJ et al. "Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis." BMJ, 2010. DOI: 10.1136/bmj.c3691.” doi.org
- BMJ, via PubMed. “Bolland MJ et al. "Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis." BMJ, 2011. DOI: 10.1136/bmj.d2040.” doi.org
- Endocrinology and Metabolism (Seoul), via PubMed. “Reid IR, Birstow SM, Bolland MJ. "Calcium and Cardiovascular Disease." Endocrinol Metab (Seoul), 2017. DOI: 10.3803/EnM.2017.32.3.339.” doi.org